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Summary 
Virus shedding from the epithelial cells of the serous acini of salivary glands is a major source 
for the horizontal  transmission  of cytomegalovirus.  These cells  are,  different to other tissues, 
exempt from CD8 T  lymphocyte control.  CD4 T  lymphocytes are essential to terminate  the 
productive infection.  Here, we prove that  T-B cooperation and the production  of antibodies 
are not required for this process. For the infection with murine cytomegalovirus, mutant mice 
were used which  do  not  produce  antibodies  because of a  disrupted  membrane  exon  of the 
immunoglobulin  #  chain gene.  Also, in these mice the virus clearance from salivary glands is 
a function of CD4 T lymphocytes. However, these mice clear the virus and establish viral latency 
with a kinetics that is distinguishable from normal mice. Reactivation from virus latency is the 
only stage at which the absence of antibodies alters the phenotype of infection. In immunoglobulin- 
deficient mice, virus recurrence results in higher virus titers. The adoptive serum transfer proved 
that antibody is the limited factor that prevents virus dissemination in the immunodeficient host. 
C 
MV, like the other members of the herpesvirus family, 
cannot be eliminated by the infected host despite an in- 
tact immune system. Immune effector mechanisms are also 
unable to prevent virus reactivation from latency. Neverthe- 
less, there is a clear evidence that immune functions play the 
decisive role in CMV control because a deficiency in specific 
immune functions can result in various degrees and patterns 
of disease manifestations,  and even in fatal disease (reviewed 
in reference  1).  Several  therapeutic  regimens  are associated 
with long-lasting immunosuppression and the risk of CMV 
disease. Bridging the period of immunodeficiency by passive 
transfer of the essential immune functions that  limit virus 
infection is a medical goal. Clinical correlation predicts and 
experiments  in the mouse model using the murine  CMV 
(MCMV) prove that specific cellular effector mechanisms have 
a strong protective function (reviewed in references 2 and 3). 
In the mouse,  the adoptive transfer  of T  lymphocytes has 
a prophylactic as well as a therapeutic effect (3-6). The MHC 
restriction of CD8 T lymphocyte functions, however, makes 
this form of therapy cumbersome in humans  (7). 
A protective role for administered antibodies is indicated 
by animal models (8, 9). It has been a point of debate in the 
field, however, whether passive immunization with antibodies 
is a suitable form of prophylaxis and therapy for human CMV 
disease (10). The physiological function of antibodies during 
natural CMV infection is not dearly defined. This may hamper 
the improvement  of the clinical  application  of specific  an- 
tisera. T h cell and antibody functions have not been rigorously 
distinguished. An otherwise functional immune system, solely 
devoid of B cells and antibodies, has not been confronted with 
CMV infection. Elimination  of CD4 helper cells, however, 
deprives the host from the cell type essential for clearance 
of the salivary gland. This results in chronic local virus repli- 
cation to high  titers  (11). 
Recently, by targeted mutagenesis,  mice with a deletion 
of the transmembrane exon of the Ig # chain have been pre- 
pared. These mice are devoid of B cells and do not produce 
any antibody but are normal with respect to other immune 
effector functions (12). We used these mice in order to study 
whether the lack of specific antibody would affect either the 
virus clearance during recovery from acute infection or the re- 
currence from latency,  or both. Here, we report that the ab- 
sence of antibodies does not alter the course and the kinetics 
of primary MCMV infection, but affects virus spread during 
recurrent  infection. 
Materials and Methods 
Mice.  6-8-wk-old mice, either homozygous  (#MT/#MT) or 
heterozygous (#MT/+) for # chain mutation, and normal C57BL/6 
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introduction of embryonic stem cells carrying a disrupted # chain 
gene into C57BL/6 mice (12). The animals used were obtained 
by mating  homozygous  males and  heterozygous  females. The 
homozygous and heterozygous offspring were selected by testing 
sera in a sandwich ELISA for the presence of IgM antibodies. B 
cell deficiency was tested by cytofluorometry for the absence of 
CD45R(B220) + and  IgM § cells in  the  spleen of homozygous 
animals. 
Virus, Infection Conditions, and Virus Titrations.  The Smith strain 
of MCMV (VK-194; American Type Culture Collection,  Rock- 
ville, MD) was propagated in third-passage mouse embryo fibro- 
blasts (MEF) and purified by pelleting through a sucrose cushion 
as described previously (4). Animals were infected by injection of 
2  x  10  s PFU of MCMV into one hind footpad. The virus titers 
in organ homogenates were determined in MEF by an in vitro plaque 
assay with centrifugal enhancement of infectivity (4). To prevent 
secondary plaque formation,  methylcellulose was used which re- 
stricted detection limit to 100 PFU per organ. To fully exploit the 
sensitivity of the assay, the rest of the organ homogenates (diluted 
1:100) were plated on the test 48-weU plates without methylcellu- 
lose, and plaques were counted 5-10 d later. By this procedure the 
detection limit was increased to one PFU per organ. 
Neutralization Assay.  The neutralization of MCMV in vitro was 
done as described previously (13). Briefly, MCMV was mixed with 
serially diluted mouse serum (inactivated at 56~  for 30 min) and 
with rabbit complement.  After incubation  for 60 min at 37~ 
the plaque assay was performed. 
ELISA.  Presence of IgM in the sera of mice was determined 
by a quantitative  sandwich ELISA (14). Rabbit anti-mouse IgM 
(Dianova, Hamburg, Germany) was used for coating of the plates, 
and peroxidase-conjugated rabbit anti-mouse IgM (Dianova) was 
used for detection oflg binding. Purified mouse IgM (Sigma Chem- 
ical Co., St. Louis, MO) served as a standard. MCMV-specific  anti- 
bodies in sera of infected mice were also determined by an ELISA 
(13). Serial dilutions of sera were made and antibody binding was 
detected by peroxidase-conjugated anti-mouse Ig (Dianova), using 
o-phenylenediamine as the substrate. Tests were done in four repli- 
cates. The last serum dilution resulting in an OD at 492 nm plus 
3 SD above  the mean of  nonimmune sera was taken as the final titer. 
Reactivation of Latent MCMV.  Recurrence was induced in la- 
tently infected mice by 6 Gy y-irradiation  followed by a single in- 
jection of 1 mg of cytolytic mAbs to CD4 (YTS 191.1) (15), to 
CD8 (YTS 169.4) (15), and to NKI.1 (PK136), which recognizes 
the majority of NK cells (16). The antibodies used for injection 
were prepared from ascitic fluid by double ammonium  sulphate 
precipitation. In addition, animals were injected with hydrocorti- 
sone sodium succinate (125 mg/kg/i.m.) every other day. Animals 
were killed 2 wk after initiation  of the reactivation protocol and 
virus titers in several organs were determined. 
Detection of Viral DNA.  Organs of MCMV-infected mice were 
isolated 12 wk after infection. Half of the organ material was used 
to detect infectious virus. Organ material from mice without any 
productive infection was then used for DNA isolation. Specific  viral 
and cellular DNA sequences were amplified by PCK, as described 
elsewhere (17). Briefly, a 363-nucleotide sequence was amplified 
from exon 4 of MCMV immediate-early gene iel by using oligo- 
nucleotide IE1.1983 and IE.2345 as forward and reverse primer, 
respectively, and  oligonucleotide  IE1.2135 as  the probe for the 
verification of the identity of the amplification product. For nega- 
tive control, the samples containing all components except the organ 
DNA were used. The 12.2-kb pair circular plasmid piE111, which 
encompasses the genes iel and ie3 of MCMV (18), served as a posi- 
tive control. 
Results and Discussion 
Antibodies Do Not Terminate Organ Infection and Horizontal 
Transmission  of CMV.  We have reported earlier that clear- 
ance of MCMV from various tissues  requires the functions 
associated with CD8 T lymphocytes (4-6, 19). The only ex- 
ceptions are the salivary glands where the function of CD4 
T cells is necessary (11). CD4 T lymphocyte subset-depleted 
mice establish a long-term persistent infection in acinar glan- 
dular epithelial cells (11). Adoptive cell transfer studies have 
shown that the CD4 T lymphocyte effector function requires 
the contribution of other cells (20). The CD4 T lymphocyte 
function is  associated  with  the release  of IFN-3' (21)  and 
TNF-t~ (22). In the absence of CD4 T lymphocytes the specific 
antibody response is also prevented (20, 21). Thus, we were 
not able to distinguish between the physiological contribu- 
tion of CD4 T lymphocytes and antibodies. To address this 
question, we used mice that lack membrane Ig expression 
and that are deficient in B cell maturation. Mice homozy- 
gous for # chain mutation (#MT/#MT) were infected with 
MCMV, and the clearance kinetics was compared with that 
of their heterozygous littermates (#MT/+) having normal 
B cell response, and with the clearance in normal C57BL/6 
(+/+)  mice (Fig.  1).  The pattern of virus replication and 
clearance in B cell-deficient mice was indistinguishable from 
that in heterozygous mice and normal C57BL/6 mice. Within 
7 wk after infection with tissue culture-grown MCMV, all 
three groups of mice terminated primary infection. Produc- 
tive infection was mainly restricted to the salivary  glands, 
but no difference in clearance kinetics was observed between 
the three experimental groups. With the exception of an oc- 
casional  finding in individual mice of all three groups, the 
virus did not replicate in the lungs, liver, or spleen (data not 
shown). We then asked whether a role of antibodies would 
be detectable during the clearance of the salivary gland iso- 
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Figure  1.  Kinetics  of resolution  of  primary  infection  in salivary  glands. 
Normal C57BL/6 (+/+) and mice, homozygous  (#MT/#MT) or hetero- 
zygous (#MT/+) for the # chain mutation were infected with MCMV 
and the virus titer in salivary glands was determined. Titers  of individual 
mice (sTmbols) and median values (horizontal bars) are shown. 
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Figure 2.  Absence  of  antibody  response  to 
MCMV in B cell-deficient  mice. Sera from (0) 
/zMT//zMT, (El) #MT/+, and (O) +/+ mice were 
obtained  at different  time periods  after infection 
and were analyzed for the presence of antibodies 
to MCMV by (.4) ELISA and by (/3) virus-neutrali- 
zation.  Data represent  the mean value from five 
individual  samples. 
late of MCMV. Mice infected with this more virulent virus 
showed a prolonged virus replication, and the low-level per- 
sistency in salivary glands could be found even at 3 mo after 
the infection. However, there was again no difference in the 
protracted clearance pattern between these three groups of 
mice (data not shown).  Inability to produce antiviral  anti- 
bodies in B cell-deficient mice was verified by ELISA and 
by the virus neutralization assay (Fig. 2). No detectable reac- 
tivity was found in sera from homozygous B cell-deficient 
mice by ELISA, whereas the heterozygous littermates devel- 
oped an antibody response that was indistinguishable  from 
normal  C57BL/6  mice  (Fig.  2 A).  Serum  from MCMV- 
primed,  B cell-deficient mice lacked virus-neutralizing  ac- 
tivity (Fig.  2 B). In contrast, the sera derived from MCMV- 
primed heterozygous mice showed a neutralizing titer similar 
to that of MCMV-primed normal C57BL/6 mice reaching 
high neutralizing  titers after 2 wk.  Note that plateau titers 
were reached before the elimination  of infectious virus. 
We had previously observed a plasticity of the immune 
control of MCMV infection (20). For example, although CD8 
T  lymphocytes are  usually essential  and  also  sufficient  to 
combat MCMV infection, the situation is different in mice 
that lack CD8 T  lymphocytes altogether.  CD4 T  lympho- 
cytes of these mice limit virus spread and,  when  tested in 
adoptive cell transfer systems, also protect the passively trans- 
ferred and infected recipients  (20).  We therefore analyzed, 
whether in the B cell-deficient mouse the CD4 T  lympho- 
cyte subset still has the decisive role in salivary  gland clear- 
ance as in normal mice. Fig. 3 shows that this is indeed the 
case, because the elimination of the CD4, but not of CD8 
T lymphocyte subset abrogates virus clearance from the sali- 
vary glands.  In conclusion, by using the B cell-deficient mice, 
we demonstrate that antibodies are neither essential for the 
resolution of primary infection in general, nor for the preven- 
tion  of horizontal  virus  spread. 
Antibodies Prevent CMV Dissemination after Recurrence in the 
Immunosuppressed Host.  We were interested to learn, whether, 
irrespective of the clearance kinetics, the lack of B cells could 
alter the fate of tatently infected mice. Recently, we have de- 
scribed that  the conditions of primary infection define the 
load of latent viral genome in organs,  and thus the risk of 
recurrent CMV disease (23). The copy number of latent viral 
genome in tissues was defined as the key parameter that de- 
termines the overall and organ-specific risk of recurrence. We 
had observed that the burden of latent CMV was related to 
the extent of virus multiplication during primary infection. 
Testing of the latent  viral genome load in B  cell deficient 
and normal mice led to identical results and corroborated again 
that these mice do not differ in their clearance kinetics (Fig. 4). 
The prophylactic serum transfer, with and without specific 
antibodies, into irradiated and infected naive mice provided 
a surrogate for testing the role of antibodies after virus recur- 
rence from latency. In that situation, presence of antibodies 
caused a difference in virus titers of three to four orders of 
magnitude in salivary gland and lungs (23). Therefore, after 
establishment of latency, B cell-deficient mice were subjected 
to the induction of recurrence in vivo in order to test whether 
the lack of antibody would alter the propagation properties 
of recurrent virus. The immunosuppressive protocol led to 
the reactivation in all experimental  groups (Fig.  5). When 
we tested the titer of the recurrent virus in the B cell-deficient 
mouse, a clear difference in organ virus titers was detected. 
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Figure  3.  Effect of CD4 and 
CD8 T lymphocyte depletion on 
MCMV clearance from salivary 
glands  of B cell-deficient  mice. 
(O)  Normal (+/+)  and  (Q)  B 
cell-deficient  (/~MT/pMT) mice 
were depleted of CD4 or CD8 T 
lymphocytes  (20)  and  infected 
with 2  x  10  s PFU of MCMV. 
The virus titer in salivary glands 
was determined 3 wk later. Titers 
of individual  mice (symbols) and 
median values (horizontal Mrs) are 
shown.  (DL) Detection limit. Figure 4.  Determination of la- 
tent DNA load in the lungs of B 
cell-deficient mice. 5 #g of DNA 
extracted from the lungs, a major 
site of CMV latency  (17), of six in- 
dividual mice (a-J) per group were 
analyzed by PCK for the presence 
of  viral  DNA. Different  copy  num- 
bers of IE 111 plasmid (in log 10 
steps), mixed with 5/xg of carrier 
DNA, served  as a positive  control. 
(~)  All  reagents except plasmid 
DNA. 
Salivary glands  Lungs  Spleen 
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Figure 5.  High  virus titers after reactivation in  B 
cell-deficient mice. Latently infected mice (12 wk after 
infection)  were subjected  to immunosuppressive  treatment 
and virus titers in organs were determined  2 wk later (O). 
Control mice were tested for infectious virus in tissues 
on the day of immunosuppressive  treatment (O). Titers 
of individual mice (symbols)  and  the  median values 
(horizontal  bars) are shown. 
The organs  from normal and heterozygous mice contained 
100-1,000-fold less infectious virus than the organs from the 
group of homozygous littermates. Transfer of immune serum 
into B cell-deficient mice provided proof that it was in fact 
Spleen  Lungs 
t   MT/ MT  I   J+ll 
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Figure  6.  Adoptive  immune serum transfer prevents virus dissemina- 
tion during recurrence. Latently infected B cell-deficient mice were first 
treated with MCMV-specific  serum derived  from latently infected  hetero- 
zygous mice and then subjected to immunosuppressive  treatment. Each 
mouse received  0.5 ml i.p. of immune serum every  8 h (2.5 ml of immune 
serum altogether). After the last injection of serum, MeMV-specific  anti- 
body titer in serum-transfer recipients were comparable with those in 
seropositive heterozygous. Virus titers were determined 2 wk later. 
the lack of antibody that allowed the spread of virus in this 
group  (Fig.  6). 
Altogether,  the data show that during primary infection 
there is no detectable physiological role for antibodies regarding 
the organ clearance and the prevention of horizontal trans- 
mission. The capacity to produce specific antibodies did not 
affect the clearance kinetics, the establishment of latency, or 
the burden  of latent  DNA.  A  clear physiological role for 
specific antibody,  however,  is  seen  after virus  reactivation. 
During recurrence, the presence of neutralizing antibody has 
a significant effect on virus spread, which proves our predic- 
tion on the role of antibodies in limiting the spread of virus 
after focal recurrence (23). We explain the difference of anti- 
body function between primary infection and recurrence by 
the distribution of virus at intraceUular and extracellular sites. 
We hypothesize that at the time of an effective antibody re- 
sponse  during primary infection,  the majority of CMV  is 
already located at intraceUular sites that are resistant  to the 
effect of antibody. During recurrence after immunosuppres- 
sion, however, antibodies are the only specific immune func- 
tion  that  limits  extracellular dissemination. 
Two aspects require further attention. First, it remains enig- 
matic why the productively infected cell is resistant  to the 
antibody effect. Is there a specific evasion mechanism of CMV 
to escape the function of antibodies? Second, these data prove 
that the CD4 T lymphocyte subset, which controls the virus 
spread between individuals, operates in the absence of B cells. 
Further studies will show how the cytokines defined earlier 
(21,  22)  recruit other  effector cells  to this  task. 
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